Findings from the Lancet Diabetes & Endocrinology meta-analysis and prior 2023 research indicated that replacing red meat with nuts, legumes, or dairy significantly lowers the risk of developing type 2 diabetes.

Criticism following the January 2026 release of the 2025-2030 Dietary Guidelines for Americans was unusually broad due to transparency concerns and reported panel ties to industry groups.

552c7ae14Claim

A March 2026 poll published in the American Journal of Preventive Medicine showed that 50% of U.S. adults doubted the scientific basis of the dietary guidelines and 44% found them unhelpful.

552c7ae14Claim

The Physicians Committee for Responsible Medicine alleges that federal authorities failed to publish a public charter or meeting notices for the panel that drafted the 2025-2030 Dietary Guidelines.

552c7ae14Claim

The Physicians Committee for Responsible Medicine filed a lawsuit in U.S. District Court in Washington, D.C., seeking to force the withdrawal and lawful reissuance of the 2025-2030 Dietary Guidelines for Americans.

552c7ae14Claim

The Physicians Committee for Responsible Medicine alleges that the panel convened to write the 2025-2030 Dietary Guidelines was drawn from meat, dairy, supplement, and fad diet industries.

552c7ae14Claim

The Physicians Committee for Responsible Medicine contends in its legal complaint that federal officials violated administrative law by releasing dietary guidelines created through a process lacking transparency and balanced representation.

552c7ae14Claim

Litigation over the 2025-2030 Dietary Guidelines for Americans resembles an ongoing federal lawsuit in which a judge temporarily halted child immunization panel recommendations due to unlawful HHS appointments.

552c7ae14Claim

A legal scholar stated that the Administrative Procedure Act prohibits arbitrary agency action, noting HHS discarded scientific committee decisions without adequate justification or convincing evidence.

552c7ae14Claim

More than 200 medical and research professionals sent a letter to HHS and USDA warning that the 2025-2030 Dietary Guidelines lacked scientific evidence and could harm public health.

552c7ae14Claim

The Physicians Committee for Responsible Medicine alleges that HHS bypassed a 20-expert scientific advisory report to rapidly convene a separate panel without outside oversight or public participation.

552c7ae14Claim

Study authors proposed bariatric surgery serve as a first-line treatment for clinical obesity, but as a second-line risk-reduction option for preclinical obesity as pharmacotherapy expands.

552c7ae14Claim

Clinical obesity prevalence among metabolic bariatric surgery candidates varied across international centers, ranging from 62.7% in the Brazilian cohort to 79.3% in the United Kingdom cohort.

552c7ae14Claim

Mean body mass index and distribution across BMI categories (<40, 40-49, and ≥50) did not differ significantly between clinical and preclinical obesity groups within surgical centers.

552c7ae14Claim

Study authors noted bariatric surgery in clinical obesity may offer faster economic returns due to reduced post-operative complications, decreased medication use, and fewer hospitalizations.

552c7ae14Claim

Bariatric surgery patients with clinical obesity lost modestly less weight post-surgery, trailing preclinical obesity patients by 2 to 4 percentage points in several study cohorts at 12 and 24 months.

552c7ae14Claim

Study authors stated bariatric surgery for preclinical obesity should be evaluated as a preventive intervention with longer time horizons and distinct cost-effectiveness thresholds.

552c7ae14Claim

Study authors suggested health systems with limited surgical capacity prioritize metabolic bariatric surgery for patients demonstrating clinical obesity-related organ dysfunction.

552c7ae14Claim

A Lancet Diabetes & Endocrinology Commission led by Dr. Francesco Rubino in January 2025 proposed separating clinical obesity from preclinical obesity based on organ dysfunction.

Findings from the Lancet Diabetes & Endocrinology meta-analysis and prior 2023 research indicated that replacing red meat with nuts, legumes, or dairy significantly lowers the risk of developing type 2 diabetes.

Diet and exercise interventions alone are not enough to reverse the rise in childhood obesity

Weight-loss medications are appropriate as a first-line treatment for adolescents with obesity

Criticism following the January 2026 release of the 2025-2030 Dietary Guidelines for Americans was unusually broad due to transparency concerns and reported panel ties to industry groups.

A March 2026 poll published in the American Journal of Preventive Medicine showed that 50% of U.S. adults doubted the scientific basis of the dietary guidelines and 44% found them unhelpful.

The Physicians Committee for Responsible Medicine alleges that federal authorities failed to publish a public charter or meeting notices for the panel that drafted the 2025-2030 Dietary Guidelines.

The Physicians Committee for Responsible Medicine filed a lawsuit in U.S. District Court in Washington, D.C., seeking to force the withdrawal and lawful reissuance of the 2025-2030 Dietary Guidelines for Americans.

The Physicians Committee for Responsible Medicine alleges that the panel convened to write the 2025-2030 Dietary Guidelines was drawn from meat, dairy, supplement, and fad diet industries.

The Physicians Committee for Responsible Medicine contends in its legal complaint that federal officials violated administrative law by releasing dietary guidelines created through a process lacking transparency and balanced representation.

Litigation over the 2025-2030 Dietary Guidelines for Americans resembles an ongoing federal lawsuit in which a judge temporarily halted child immunization panel recommendations due to unlawful HHS appointments.

A legal scholar stated that the Administrative Procedure Act prohibits arbitrary agency action, noting HHS discarded scientific committee decisions without adequate justification or convincing evidence.

More than 200 medical and research professionals sent a letter to HHS and USDA warning that the 2025-2030 Dietary Guidelines lacked scientific evidence and could harm public health.

The Physicians Committee for Responsible Medicine alleges that HHS bypassed a 20-expert scientific advisory report to rapidly convene a separate panel without outside oversight or public participation.

Study authors proposed bariatric surgery serve as a first-line treatment for clinical obesity, but as a second-line risk-reduction option for preclinical obesity as pharmacotherapy expands.

Clinical obesity prevalence among metabolic bariatric surgery candidates varied across international centers, ranging from 62.7% in the Brazilian cohort to 79.3% in the United Kingdom cohort.

Mean body mass index and distribution across BMI categories (<40, 40-49, and ≥50) did not differ significantly between clinical and preclinical obesity groups within surgical centers.

Study authors noted bariatric surgery in clinical obesity may offer faster economic returns due to reduced post-operative complications, decreased medication use, and fewer hospitalizations.

Bariatric surgery patients with clinical obesity lost modestly less weight post-surgery, trailing preclinical obesity patients by 2 to 4 percentage points in several study cohorts at 12 and 24 months.

Study authors stated bariatric surgery for preclinical obesity should be evaluated as a preventive intervention with longer time horizons and distinct cost-effectiveness thresholds.

Study authors suggested health systems with limited surgical capacity prioritize metabolic bariatric surgery for patients demonstrating clinical obesity-related organ dysfunction.

A Lancet Diabetes & Endocrinology Commission led by Dr. Francesco Rubino in January 2025 proposed separating clinical obesity from preclinical obesity based on organ dysfunction.